Skip to main content
. 2020 Aug 24;43(8):718–727. doi: 10.14348/molcells.2020.0065

Fig. 1. The effect of LncRNA CRNDE knockdown on the BCP-ALL cell lines.

Fig. 1

The expression level of LncRNA CRNDE was measured in the (A) BM samples collected from patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL, n = 26) and controls (n = 15) and in (B) normal primary precursor B-cells (Normal) and BCP-ALL cell lines (NALM-6, RS4;11, CEMO-1, CCRF-SB, and SUP-B15) using qRT-PCR. Then, NALM-6 and RS4;11 cells were transfected with shRNA-CRNDE or its negative control (shRNA). (C and H) The expression level of LncRNA CRNDE was measured using qRT-PCR in NALM-6 cells and RS4;11 cells, respectively. (D and I) Cell viability was measured using the MTT assay in NALM-6 cells and RS4;11 cells, respectively. (E and J) Cell proliferation was measured using the bromodeoxyuridine (BrdU) assay in NALM-6 cells and RS4;11 cells, respectively. (F and K) The protein levels of cleaved (cl-) caspase 3, total (T) caspase 3, cleaved poly ADP-ribose polymerase (cl-PARP), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X (Bax) were measured using Western blot in NALM-6 cells and RS4;11 cells, respectively. Β-actin was used as an internal control. (G and L) Cell apoptosis was measured using flow cytometry in NALM-6 cells and RS4;11 cells, respectively. *P < 0.05, **P < 0.01, ***P < 0.001 vs control or Normal or shRNA.